Publication | Closed Access

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

5-Year AnalysisBreast OncologyMedicineRandomised TrialImmunologyBreast CancerCancer TreatmentOncologyRadiation OncologyNeoadjuvant Pertuzumab